Yahoo · Oct 24, 2026
Amneal Pharmaceuticals (AMRX) Faces A Valuation Test Following Slowing Growth Concerns
Amneal Pharmaceuticals (AMRX) is back in focus after commentary highlighting slowing sales growth, softer earnings per share trends, and weaker returns on capital that point to execution challenges inside the business. The recent commentary comes after a powerful run in the stock. Amneal Pharmaceuticals has posted a year to date share price return of 60.98% and a 1 year total shareholder return of 93.18%, while the 3 year total shareholder return is more than four times the starting capital...

